COMPANY:

Viome

"Viome Life Sciences said Tuesday it has raised $67 million as part of a Series C financing round, which it will use to expand research into assays targeting aggressive cancers and chronic diseases, as well as clinical validation of early-stage diagnostics and therapeutics."

"Viome Life Sciences, a mission-driven biotechnology company, announces the arrival of its CancerDetect™ test for oral & throat cancer, the first to launch in a series of diagnostic tests in development. This test is the first to detect biomarkers for early-stage oral and throat cancers based on technology that has received FDA Breakthrough Device Designation. CancerDetect™ is available to individuals at higher risk of developing these cancers, fulfilling an unmet need for advanced, earlier detection when it is most easy to treat. Viome's launch of the CancerDetect™ signifies a promising future for saliva-based, early cancer detection testing with Viome's advanced mRNA technology and AI-powered platform."

"After several years marketing direct-to-consumer, microbiome wellness testing...Viome is taking its first step into the clinical diagnostics market, announcing this month that it is developing a saliva-based oral and throat cancer detection test that has received Breakthrough Device Designation from the US Food and Drug Administration."

"Viome...today announced its proprietary mRNA analysis technology combined with its next-generation AI platform has been designated a Breakthrough Device by The Food and Drug Administration (FDA) for early detection of oral cancer and throat cancer."